<DOC>
	<DOCNO>NCT00352144</DOCNO>
	<brief_summary>To evaluate long-term efficacy eszopiclone administer 6 month subject primary insomnia subjective sleep measure , compare placebo .</brief_summary>
	<brief_title>6-Month Chronic Efficacy &amp; Safety Study Eszopiclone Adult Subjects With Primary Insomnia</brief_title>
	<detailed_description>This double blind , randomize ( 2:1 ; eszopiclone : placebo ) , placebo-controlled , multicenter , study eszopiclone subject primary insomnia . The study involve 9 visit subject participation approximately 224 day . After meet screen criterion , subject randomize either eszopiclone 3 mg QD placebo . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Inclusion Criteria Subject meet DSMIV criterion primary insomnia report sleep 6.5 hour per night and/or take 30 minute night fall asleep least one month prior screen . Male female subject must 21 64 year age , inclusive , time consent . Female subject childbearing potential must sign Women Childbearing Potential Addendum inform consent form . Females consider childbearing potential must surgically sterile great oneyear post menopausal , define complete cessation menstruation least one year . Subject must general good health , base screen physical examination ( include brief neurological examination ) , medical history , 12lead ECG , clinical laboratory value ( hematology , serum chemistry urinalysis ) . Exclusion Criteria Subject clinically significant unstable medical abnormality , chronic disease , history clinically significant abnormality cardiovascular , respiratory , hepatic , renal system . Subject history cancer within past 5 year , current malignancy except non melanomatous skin cancer . Subject psychiatric diagnosis psychosis , dementia delirium . Subjects Sexual Gender Identity Disorders nonpsychotic disorder consider casebycase basis . Subject one follow Personality Disorders : schizotypal , schizoid , borderline personality disorder . Subject difficulty sleep initiation maintenance associate know medical diagnosis ( e.g . sleep apnea , restless leg syndrome ( RLS ) , periodic leg movement syndrome ( PLMS ) , condition may affect sleep ( e.g. , chronic pain , BPH , etc. ) . Subject participate previous eszopiclone clinical trial . Subject know sensitivity racemic zopiclone , benzodiazepine , sedative hypnotic , substance contain formulation , hospitalize allergic condition ( e.g . recurrent dermatitis , drug hypersensitivity , drug allergy , etc. ) . Subject history substance abuse past 10 year substance dependence time positive urine drug test screening . Subject test positive screen hepatitis B surface antigen , hepatitis C antibody history positive result . Subject know seropositive HIV . Female subject pregnant , lactate within 6 month post partum . Subject selfreports consumption two alcoholic beverage daily , 14 alcoholic beverage weekly , five alcoholic beverage give day . Subject take psychotropic medication medication know affect sleep within 3 day prior screen visit anticipate need type medication doubleblind treatment . Subject participate investigational study within 30 day prior screen . Subject take herbal supplement , purported central nervous system effect , ( tablet , powder , extract tincture ) combination product herbs melatonin within 14 day prior screen St. John 's Wort within 30 day prior screen . Subject rotate third/night shift worker . Subject staff member relative staff member .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>